Phase 4 Study: Long-term Safety and Efficacy of NT-501 in MacTel Type 2, Including Sham Procedure Participants

Scheie Eye Institute, Philadelphia

National Eye Institute, Bethesda

Elman Retina Group, PA, Baltimore

Cumberland Valley Retina Consultants, Frederick

Emory Eye Center, Atlanta

Southeastern Retina Associates, P.C., Knoxville

Retina Associates of Cleveland, Inc., Cleveland

Cincinnati Eye Institute, Cincinnati

Foundation for Vision Research, Grand Rapids

University of Wisconsin, Madison

Mayo Clinic, Rochester

Northwestern University, Chicago

The Retina Institute, St Louis

Tulsa Retina Consultants, Tulsa

Texas Retina Associates, Dallas

Retina Center of Texas, Dallas

Retina Consultants of Texas, Houston

University of Utah John A. Moran Center, Salt Lake City

Jules Stein Eye Institute/UCLA, Los Angeles

Scripps Health, La Jolla

Stanford University School of Medicine, Palo Alto

Bay Area Retina Associates, Walnut Creek

Retina Northwest, P.C., Portland

Massachusetts Eye and Ear Infirmary, Retina Service, Boston

Envision Ocular, LLC, Bloomfield

Cerulea, East Melbourne

Lion's Eye Institute, Perth

Sydney Eye Hospital, Sydney

Lariboisiére Hospital, Paris

University Eye Hospital Bonn, Bonn

UNIVERSITÄTSKLINIKUM FREIBURG, Klinik für Augenheilkunde, Freiburg im Breisgau

Augenzentrum am St. Franziskus-Hospital, Münster

Oxford University Hospitals NHS FT, Oxford